Literature DB >> 6732198

DA strain of Theiler's murine encephalomyelitis virus induces demyelination in nude mice.

R P Roos, R Wollmann.   

Abstract

DA strain of Theiler's murine encephalomyelitis virus produces a chronic, progressive demyelinating disease in mice that resembles multiple sclerosis. An immunopathological mechanism for demyelination has been postulated, because there is a brisk immune response with low virus titers at the time of demyelination and because immunosuppression lessens the degree of demyelination. We inoculated Nude mice with DA virus to clarify the role of immune-mediated demyelination. Animals became paralyzed 3 weeks to 2 months after inoculation, usually dying within a week of appearance of signs. Demyelinated foci were present in the spinal cords, with evidence of degenerating myelin around intact axons as well as completely demyelinated, naked axons. Occasional macrophages were present, but none was seen actively stripping intact myelin lamellae. These results suggest that DA virus lytic infection, without a contribution from the T lymphocyte immune system, is sufficient to produce demyelination. It is likely that DA virus demyelination has varying mechanisms that may be active at different times.

Entities:  

Mesh:

Year:  1984        PMID: 6732198     DOI: 10.1002/ana.410150516

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

1.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

2.  The interaction of two groups of murine genes determines the persistence of Theiler's virus in the central nervous system.

Authors:  J F Bureau; X Montagutelli; S Lefebvre; J L Guénet; M Pla; M Brahic
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Role of the humoral immune response in resistance to Theiler's virus infection.

Authors:  C P Rossi; E Cash; C Aubert; A Coutinho
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection.

Authors:  M Yamada; A Zurbriggen; R S Fujinami
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

5.  The L-coding region of the DA strain of Theiler's murine encephalomyelitis virus causes dysfunction and death of myelin-synthesizing cells.

Authors:  G D Ghadge; R Wollmann; G Baida; M Traka; R P Roos
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

6.  Glucocorticoid exposure alters the pathogenesis of Theiler's murine encephalomyelitis virus during acute infection.

Authors:  Erin E Young; Thomas W Prentice; Danielle Satterlee; Heath McCullough; Amy N Sieve; Robin R Johnson; Thomas H Welsh; C Jane R Welsh; Mary W Meagher
Journal:  Physiol Behav       Date:  2008-05-07

7.  A subgenomic segment of Theiler's murine encephalomyelitis virus RNA causes demyelination.

Authors:  Gleb Baida; Brian Popko; Robert L Wollmann; Spyridon Stavrou; Wensheng Lin; Maria Tretiakova; Thomas N Krausz; Raymond P Roos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

8.  Transgenic expression of viral capsid proteins predisposes to axonal injury in a murine model of multiple sclerosis.

Authors:  Aleksandar Denic; Laurie Zoecklein; Jason Kerkvliet; Louisa Papke; Ramakrishna Edukulla; Arthur Warrington; Allan Bieber; Larry R Pease; Chella S David; Moses Rodriguez
Journal:  Brain Pathol       Date:  2011-02-11       Impact factor: 6.508

Review 9.  Neuroimmune interactions in a model of multiple sclerosis.

Authors:  C Jane Welsh; Andrew J Steelman; Wentao Mi; Colin R Young; Ralph Storts; Thomas H Welsh; Mary W Meagher
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

10.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.